Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year. You can read the ICAT supervisor policy here.
Full NameProfessor Mary Murphy
Medicine
National University of Ireland Galway
Webpage:nuigalway.ie
Email Address:Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- cell and developmental biology/regenerative medicine
- bioengineering/medical devices
- clinical trials
- Medicine
- Sports and Exercise Medicine
- Cardiology
- Orthopaedic surgery
- Rheumatology
My primary research interest is the development of innovative medicines to treat major diseases using adult stem cells (mesenchymal stem/stromal cells (MSCs) or MSCs derived from induced pluripotent stem cells and gene therapy as a means to provide new modalities in patient care for osteoarthritis, bone repair and vascular calcification.
Clinical research focuses on the therapeutic potential of MSCs in osteoarthritis. Basic research is focused on (1) the concept that stem cell depletion, or loss/alteration of function, contributes to development of chronic diseases such as osteoarthritis and atherosclerosis, (2) the use of chondrogenic differentiation of bone marrow-MSCs as a model to study early changes that occur in osteoarthritis development/calcification and (3) the role of inflammation in disease progression.
Tissue engineering concepts are targeted at 1) development of novel materials for cartilage repair, 2) the use of MSCs and implant surface modification for increased implant osseointegration joint replacement surgeries and 3) the development of targeting strategies and drug delivery modalities for non-invasive delivery of therapeutic cells and/or anti-inflammatory, pro-chondrogenic drugs to joints using micro- and nano-particles.
Applied research focuses on scalable, robotic manufacturing of therapeutic MSCs and addresses novel fully defined serum/medium for cell growth and scale-up for economic manufacture.